Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jun;8(3):2210-2219.
doi: 10.1002/ehf2.13313. Epub 2021 Mar 21.

SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis

Yuling Yan  1 , Bin Liu  1 , Jun Du  1 , Jing Wang  1 , Xiaodong Jing  1 , Yajie Liu  1 , Songbai Deng  1 , Jianlin Du  1 , Qiang She  1
Affiliations
Meta-Analysis

SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis

Yuling Yan et al. ESC Heart Fail. 2021 Jun.

Abstract

Aims: This study aimed to determine the effects of sodium-glucose cotransporter-2 inhibitor (SGLT2i) in heart failure with reduced ejection fraction (HFrEF), compare the effect of SGLT2i with angiotensin receptor neprilysin inhibitor (ARNI), and find whether combination of SGLT2i and ARNI is better than monotherapy.

Methods and results: Embase, Medline, and Cochrane Central Registry of Controlled Trials were searched for randomized controlled trials evaluating SGLT2i or ARNI in HFrEF. And a total of six trials were included. SGLT2i was found to significantly reduce the risk of cardiovascular death or hospitalization for heart failure by 27% [hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.67-0.80], hospitalization for heart failure by 31% (HR 0.69, 95% CI 0.62-0.77), cardiovascular death by 16% (HR 0.84, 95% CI 0.74-0.95), and all-cause death by 16% (HR 0.84, 95% CI 0.75-0.94) in HFrEF only with a statistically higher risk of genital infection (risk ratio (RR) 2.78, 95% CI 1.46-5.29). The reduction in cardiovascular death or hospitalization for heart failure was of similar magnitude in patients with or without diabetes mellitus (HR 0.71, 95% CI 0.64-0.80 vs. HR 0.75, 95% CI 0.65-0.87) using SGLT2i. Indirect treatment comparison showed that SGLT2i and ARNI had similar effects on primary outcome (HR 0.93, 95% CI 0.82-1.06). And combination of SGLT2i and ARNI achieved a better prognosis performance (HR 0.68, 95% CI 0.53-0.89) compared with ARNI monotherapy.

Conclusions: SGLT2i could safely reduce cardiovascular death or hospitalization for heart failure in HFrEF regardless of diabetes mellitus status. SGLT2i and ARNI demonstrate similar effects, while combination of SGLT2i and ARNI results in a better cardiovascular protective effect.

Keywords: Angiotensin receptor neprilysin inhibitor; Heart failure with reduced ejection fraction; Meta-analysis; Sodium-glucose cotransporter-2 inhibitor.

PubMed Disclaimer

Conflict of interest statement

Yuling Yan, Bin Liu, Jun Du, Jing Wang, Xiaodong Jing, Yajie Liu, Songbai Deng, Jianlin Du, and Qiang She declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of included trials.
Figure 2
Figure 2
Meta‐analysis of the effects of SGLT2i on the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, hospitalization for heart failure, and all‐cause death in heart failure with reduced ejection fraction. CI, confidence interval; HR, hazard ratio; SGLT2i, sodium‐glucose cotransporter‐2 inhibitor.
Figure 3
Figure 3
Meta‐analysis of safety evaluation of SGLT2i on volume depletion, fracture, amputation, major hypoglycaemia, urinary tract infection, and genital infection. CI, confidence interval; RR, risk ratio; SGLT2i, sodium‐glucose cotransporter‐2 inhibitor.
Figure 4
Figure 4
Meta‐analysis of the effects of SGLT2i on the composite of cardiovascular death or hospitalization for heart failure in heart failure with reduced ejection fraction with or without DM. CI, confidence interval; DM, diabetes mellitus; HR, hazard ratio; SGLT2i, sodium‐glucose cotransporter‐2 inhibitor.
Figure 5
Figure 5
Network plot for the effects comparison between SGLT2i and ARNI on the composite of cardiovascular death or hospitalization for heart failure in heart failure with reduced ejection fraction with indirect comparison evidence from six included trials. CI, confidence interval; HR, hazard ratio; SGLT2i, sodium‐glucose cotransporter‐2 inhibitor.
Figure 6
Figure 6
Meta‐analysis of comparing the effects of combined use of SGLT2i and ARNI versus monotherapy with ARNI on the composite of cardiovascular death or hospitalization for heart failure in heart failure with reduced ejection fraction. CI, confidence interval; HR, hazard ratio; SGLT2i, sodium‐glucose cotransporter‐2 inhibitor.
See this image and copyright information in PMC

References

    1. Lee HY, Baek SH. Optimal use of beta‐blockers for congestive heart failure. Circ J 2016; 80: 565–571. - PubMed
    1. Berbenetz NM, Mrkobrada M. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta‐analysis. BMC Cardiovasc Disord 2016; 16: 246. - PMC - PubMed
    1. Muneer K, Nair A. Angiotensin‐converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease—demystifying controversies. Indian Heart J 2017; 69: 371–374. - PMC - PubMed
    1. Nochioka K, Sakata Y, Shimokawa H. Combination therapy of renin angiotensin system inhibitors and β‐blockers in patients with heart failure. Adv Exp Med Biol 2018; 1067: 17–30. - PubMed
    1. Chia N, Fulcher J, Keech A. Beta‐blocker, angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker, nitrate‐hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID2): an evidence‐based mnemonic for the treatment of systolic heart failure. Intern Med J 2016; 46: 653–662. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources